American Autonomic Society Annual Meeting 2021 LikeFollowShareCardiovascular safety and pharmacokinetics of ATH434, a novel small molecule inhibitor of α-synuclein aggregation, in adults and older adultshttps://alteritytherapeutics.com/investor-centre/news/2021/11/09/alterity-t...Share your feedbackQuestions (0)Post questionYour question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.Start the conversationAsk Alterity Therapeutics a question about this update.DiscoverShare your feedbackDiscover